We’re proud of the work we’ve done to discover and deliver new medicines to patients in need, and we are excited about how much more can be done with science as our guide. Our team draws continual inspiration and motivation from patients, caregivers and physicians, and our desire to help extends well beyond the work we do in our labs. We are always eager to hear more about how we can support you.
Our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved medicines for people with serious diseases. Unlike at many other biopharma companies, all these medicines were invented in our own laboratories and advanced under the consistent guidance of the Regeneron team.DISCOVER AVAILABLE THERAPIES
Explore our clinical trials
The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.Find Trials
Access to our medicines
Science, technology and innovation have the remarkable power to change lives. We combine these critical elements first in the labs and then in collaboration with physicians to test our new medicines in the clinic. We must continue to innovate once a medicine is approved in order to ensure that patients have adequate access to our medicines. Our access programs and policies are designed to make a meaningful difference for patients.Explore Our Access Programs
Compassionate use: Access to investigational medicines
Before a new medicine is widely available to the public, it undergoes rigorous clinical testing to ensure it meets the safety and efficacy criteria required for regulatory approval.
Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials area available. Compassionate Use, also known as expanded access in the U.S., is an approved pathway that, by design, is meant for exceptional circumstances. Our compassionate use program has certain established criteria and each request is reviewed by Regeneron’s Compassionate Use Committee.More about Compassionate
Our patient advocacy team is dedicated to understanding the patient perspective and needs of the communities impacted by the therapeutic areas we serve. We support the efforts of these communities who raise awareness, educate and empower patients to be active participants in their care.
One of the many programs we support is the American Lung Association’s "Kickin’ Asthma," a national, school-based asthma self-management program for children ages 11 to 16 (6th grade to 10th grade). This program aims to educate and empower kids to manage their asthma through a fun and interactive approach. Children learn how to recognize symptoms and their environmental triggers and to understand proper medication use.
Kickin’ Asthma is the only program that has been proven effective in teaching kids asthma self-management skills, leading to increased asthma awareness among school personnel and decreasing emergency room visits.1 As an evidence-based program, Kickin’ Asthma was also highlighted as part of best-practice recommendations for schools, community-based agencies and state health departments, and recognized as a program that is especially promising when implemented in low-income or minority communities to promote health equity.2,3Learn more about "Kickin’ Asthma"
No disease is “too small” or “too big.” We research and develop medicines for a broad range of serious medical conditions, including blindness-causing diseases, cancer, inflammatory conditions, pain, rare diseases and infectious diseases.Therapeutic research areas
Hear from the real people impacted by our medicines
Our team is leading the way in solving the human body’s most complex mysteries and working with the patient community to improve lives. Learn how we are engaging through education to meet patients where they are.HELPING PATIENTS: A YEAR IN REVIEW